Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: Incidence, features, risk factors, and outcomes

Eye (Basingstoke)

Volumn 26, Issue 12, 2012, Pages 1517-1526

  Lyall, D A M ^a   Tey, A ^b   Foot, B ^c   Roxburgh, S T D ^b   Virdi, M ^d   Robertson, C ^e   MacEwen, C J ^b  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c ROYAL COLLEGE OF OPHTHALMOLOGISTS   (United Kingdom)

^d HAIRMYRES HOSPITAL   (United Kingdom)

^e UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

endophthalmitis; intravitreal injections; wet macular degeneration

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; BEVACIZUMAB; CEFTAZIDIME; CIPROFLOXACIN; RANIBIZUMAB; VANCOMYCIN;

ADULT; AGED; ARTICLE; BLEPHARITIS; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DATA COLLECTION METHOD; DEMOGRAPHY; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; GRAM POSITIVE INFECTION; HUMAN; INCIDENCE; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RETINA MACULA AGE RELATED DEGENERATION; RISK FACTOR; UNITED KINGDOM; VISUAL ACUITY;

EID: 84871051778     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2012.199     Document Type: Article

References (49)

1. Augood CA, Vingerling JR, de Jong PT, Chakravarthy U, Seland J, Soubrane G et al. Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). Arch Ophthalmol 2006; 124: 529-535.
2. Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in England & Wales. BMC Public Health 2006; 6: 58.
3. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992; 99: 933-943.
4. Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of agerelated maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 1995; 102: 1450-1460.
5. Brown MM, Brown GC, Stein JD, Roth Z, Campanella J, Beauchamp GR. Age-related macular degeneration: economic burden and value-based medicine analysis. Can J Ophthalmol 2005; 40: 277-287.
6. Owen CG, Fletcher AE, Donoghue M, Rudnicka AR. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? Br J Ophthalmol 2003; 87: 312-317.
7. NICE. HTA Ranibizumab and Pegaptanib for the treatment of AMD. Final Scope 2006.
8. Minassian DC, Reidy A, Lightstone A, Desai P. Modelling the prevalence of age-related macular degeneration (2010-2020) in the UK: expected impact of anti-vascular endothelial growth factor (VEGF) therapy. Br J Ophthalmol 2011; 95: 1433-1436.
9. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. Ranibizumab vs verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444.
10. Day S, Acquah K, Mruthyunjaya P, Grossman DS, Lee PP, Sloan FA. Ocular complications after anti-vascular endothelial growth factor therapy in medicare patients with age-related macular degeneration. Am J Ophthalmol 2011; 152: 266-272.
11. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2011; 95: 1111-1114.
12. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
13. Saeed MU, Prasad S. Management of cataract caused by inadvertent capsule penetration during intravitreal injection of ranibizumab. J Cataract Refract Surg 2009; 35: 1857-1859.
14. Bhatt SS, Stepien KE, Joshi K. Prophylactic antibiotic use after intravitreal injection: effect on endophthalmitis rate. Retina 2011; 31: 2032-2036.
15. Cheung CS, Wong AW, Lui A, Kertes PJ, Devenyi RG, Lam WC. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology 2012; 119: 1609-1614.
16. Diago T, McCannel CA, Bakri SJ, Pulido JS, Edwards AO, Pach JM. Infectious endophthalmitis after intravitreal injection of antiangiogenic agents. Retina 2009; 29: 601-605.
17. Fintak DR, Shah GK, Blinder KJ, Regillo CD, Pollack J, Heier JS et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008; 28: 1395-1399.
18. Inoue M, Kobayakawa S, Sotozono C, Komori H, Tanaka K, Suda Y et al. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor. Ophthalmologica 2011; 226: 145-150.
19. Jonas JB, Spandau UH, Rensch F, Von Baltz S, Schlichtenbrede F. Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther 2007; 23: 240-242.
20. McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: Causative organisms and possible prevention strategies. Retina 2011; 31: 654-661.
21. Moshfeghi AA, Rosenfeld PJ, Flynn HW Jr, Schwartz SG, Davis JL, Murray TG et al. Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: A sixyear experience at a university referral center. Retina 2011; 31: 662-668.
22. Pilli S, Kotsolis A, Spaide RF, Slakter J, Freund KB, Sorenson J et al. Endophthalmitis associated with intravitreal antivascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 2008; 145: 879-882.
23. Desai P, MacEwen CJ, Baines P, Minassian DC. Incidence of cases of ocular trauma admitted to hospital and incidence of blinding outcome. Br J Ophthalmol 1996; 80: 592-596.
24. Mitry D, Charteris DG, Yorston D, Siddiqui MA, Campbell H, Murphy AL et al. The epidemiology and socioeconomic associations of retinal detachment in Scotland: A two-year prospective population-based study. Invest Ophthalmol Vis Sci 2010; 51: 4963-4968.
25. Key population and vital statistics No.34, 2007 ed. Released 24 April 2009. Office for National Statistics (www.ons. gov.uk).
26. R Development Core Team. R: A language and environment for statistical computing. R Foundation for statistical computing: Vienna, Austria, 2011.
27. Zamar D, McNeney B, Graham J. elrm: software implementing exact-like inference for logistic regression models. J Stat Softw 2007; 21.
28. Kamalarajah S, Silvestri G, Sharma N, Khan A, Foot B, Ling R et al. Surveillance of endophthalmitis following cataract surgery in the UK. Eye (Lond) 2004; 18: 580-587.
29. Lopez-Cabezas C, Muner DS, Massa MR, Mensa Pueyo JM. Antibiotics in endophthalmitis: microbiological and pharmacokinetic considerations. Curr Clin Pharmacol 2010; 5: 47-54.
30. Ng JQ, Morlet N, Pearman JW, Constable IJ, McAllister IL, Kennedy CJ et al. Management and outcomes of postoperative endophthalmitis since the endophthalmitis vitrectomy study: the Endophthalmitis Population Study of Western Australia (EPSWA)'s fifth report. Ophthalmology 2005; 112: 1199-1206.
31. Packer M, Chang DF, Dewey SH, Little BC, Mamalis N, Oetting TA et al. Prevention, diagnosis, and management of acute postoperative bacterial endophthalmitis. J Cataract Refract Surg 2011; 37: 1699-1714.
32. Almeida DR, Miller D, Alfonso EC. Anterior chamber and vitreous concordance in endophthalmitis: implications for prophylaxis. Arch Ophthalmol 2010; 128: 1136-1139.
33. Mollan SP, Gao A, Lockwood A, Durrani OM, Butler L. Postcataract endophthalmitis: incidence and microbial isolates in a United Kingdom region from 1996 through 2004. J Cataract Refract Surg 2007; 33: 265-268.
34. van Duijn PJ, Dautzenberg MJ, Oostdijk EA. Recent trends in antibiotic resistance in European ICUs. Curr Opin Crit Care 2011; 17: 658-665.
35. Barza M, Pavan PR, Doft BH, Wisniewski SR, Wilson LA, Han DP et al. Evaluation of microbiological diagnostic techniques in postoperative endophthalmitis in the Endophthalmitis Vitrectomy Study. Arch Ophthalmol 1997; 115: 1142-1150.
36. Irigoyen C, Ziahosseini K, Morphis G, Stappler T, Heimann H. Endophthalmitis following intravitreal injections. Graefes Arch Clin Exp Ophthalmol 2012; 250: 499-505.
37. Sheng Y, Sun W, Gu Y, Lou J, Liu W. Endophthalmitis after cataract surgery in China, 1995-2009. J Cataract Refract Surg 2011; 37: 1715-1722.
38. Kamalarajah S, Ling R, Silvestri G, Sharma NK, Cole MD, Cran G et al. Presumed infectious endophthalmitis following cataract surgery in the UK: A case-control study of risk factors. Eye (Lond) 2007; 21: 580-586.
39. Lundstrom M, Wejde G, Stenevi U, Thorburn W, Montan P. Endophthalmitis after cataract surgery: A nationwide prospective study evaluating incidence in relation to incision type and location. Ophthalmology 2007; 114: 866-870.
40. Montan PG, Koranyi G, Setterquist HE, Stridh A, Philipson BT, Wiklund K. Endophthalmitis after cataract surgery: risk factors relating to technique and events of the operation and patient history: A retrospective case-control study. Ophthalmology 1998; 105: 2171-2177.
41. Mason JO 3rd, White MF, Feist RM, Thomley ML, Albert MA, Persaud TO et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 2008; 28: 564-567.
42. Shah CP, Garg SJ, Vander JF, Brown GC, Kaiser RS, Haller JA. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology 2011; 118: 2028-2034.
43. Aralikatti AK, Needham AD, Lee MW, Prasad S. Entry of antibiotic ointment into the anterior chamber after uneventful phacoemulsification. J Cataract Refract Surg 2003; 29: 595-597.
44. Werner L, Sher JH, Taylor JR, Mamalis N, Nash WA, Csordas JE et al. Toxic anterior segment syndrome and possible association with ointment in the anterior chamber following cataract surgery. J Cataract Refract Surg 2006; 32: 227-235.
45. Aldave AJ, Stein JD, Deramo VA, Shah GK, Fischer DH, Maguire JI. Treatment strategies for postoperative Propionibacterium acnes endophthalmitis. Ophthalmology 1999; 106: 2395-2401.
46. Clark WL, Kaiser PK, Flynn HW Jr, Belfort A, Miller D, Meisler DM. Treatment strategies and visual acuity outcomes in chronic postoperative Propionibacterium acnes endophthalmitis. Ophthalmology 1999; 106: 1665-1670.
47. The Endophthalmitis Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group. Arch Ophthalmol 1995; 113: 1479-1496.
48. Foot B, Stanford M, Rahi J, Thompson J. The British Ophthalmological Surveillance Unit: An evaluation of the first 3 years. Eye (Lond) 2003; 17: 9-15.
49. Kelly SP, Barua A. A review of safety incidents in England and Wales for vascular endothelial growth factor inhibitor medications. Eye (Lond) 2011; 25: 710-716.